New Topical Therapeutic Options in the Management of Superficial Fungal Infections

October 2015 | Volume 14 | Issue 10 | Supplement Individual Articles | 35 | Copyright © October 2015


Joshua A. Zeichner MD

Department of Dermatology, Mount Sinai Hospital, New York, NY

  1. Markinson BC, Caldwell BD. Efinaconazole topical solution, 10%: efficacy in patients with onychomycosis and coexisting tinea pedis. J Am Podiatr Med Assoc. 2015 Apr 13. [Epub ahead of print].
  2. Rich P. Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early. J Drugs Dermatol. 2015;14(1):58-62.
  3. Vlahovic TC, Joseph WS. Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes. J Drugs Dermatol. 2014;13(10):1186-1190.
  4. Tosti A, Elewski BE.Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life. J Clin Aesthet Dermatol. 2014;7(11):25-30.
  5. Coronado D, Merchant T, Chanda S, Zane LT. J Drugs Dermatol. 2015;14(6):609-614.
  6. Elewski BE, Aly R, Baldwin SL, et al.J Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase III studies. J Am Acad Dermatol. 2015 Jul;73(1):62-9..

AUTHOR CORRESPONDENCE